Astellas To Develop Beta-Secretase Inhibitor For Alzheimer’s In Deal With CoMentis

Astellas Pharma will front $80 million, an additional $20 million equity investment and up to $660 million in development milestones for rights to CoMentis' beta-secretase inhibitor program for Alzheimer's disease